Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CVAC 
CureVac NV (CVAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CVAC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -24.88% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 663.74M USD | Price to earnings Ratio 5.43 | 1Y Target Price 7.48 |
Price to earnings Ratio 5.43 | 1Y Target Price 7.48 | ||
Volume (30-day avg) 651241 | Beta 2.53 | 52 Weeks Range 2.21 - 5.28 | Updated Date 04/1/2025 |
52 Weeks Range 2.21 - 5.28 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -493.58% |
Management Effectiveness
Return on Assets (TTM) -24.52% | Return on Equity (TTM) -54.3% |
Valuation
Trailing PE 5.43 | Forward PE 5.24 | Enterprise Value 65658696 | Price to Sales(TTM) 10.08 |
Enterprise Value 65658696 | Price to Sales(TTM) 10.08 | ||
Enterprise Value to Revenue 0.11 | Enterprise Value to EBITDA 0.36 | Shares Outstanding 224338000 | Shares Floating 123543186 |
Shares Outstanding 224338000 | Shares Floating 123543186 | ||
Percent Insiders 45.26 | Percent Institutions 18 |
Analyst Ratings
Rating 3.86 | Target Price 7.11 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CureVac NV
Company Overview
History and Background
CureVac NV, founded in 2000 in Tu00fcbingen, Germany, pioneered mRNA-based therapies. It focused initially on oncology and infectious diseases, experiencing setbacks with its COVID-19 vaccine but continues mRNA platform development.
Core Business Areas
- mRNA Technology Platform: Development of mRNA technology for various therapeutic areas including oncology, infectious diseases, and rare diseases.
- Oncology: Development of mRNA-based cancer immunotherapies. This includes collaborative efforts with other pharmaceutical companies to enhance their existing treatment options.
- Infectious Diseases: Research and development of mRNA vaccines for infectious diseases. While its COVID-19 vaccine faced challenges, the company continues to explore applications in this area.
- Rare Diseases: Utilizing mRNA to create treatments for rare genetic disorders, aiming to address unmet medical needs.
Leadership and Structure
The leadership team includes experienced executives in biotechnology and pharmaceuticals. The organizational structure is based around research and development, clinical trials, and strategic partnerships.
Top Products and Market Share
Key Offerings
- CVR050 mRNA-based COVID-19 Vaccine: CureVac's first-generation COVID-19 vaccine did not achieve widespread market adoption due to lower efficacy compared to competitors like Pfizer/BioNTech and Moderna. The company has discontinued its development. Competitors are Pfizer/BioNTech (PFE/BNTX), Moderna (MRNA).
- mRNA Cancer Immunotherapies (pipeline products): CureVac is developing mRNA cancer immunotherapies in collaboration with other companies. These are in early stages, market share unavailable. Competitors include Moderna (MRNA), BioNTech (BNTX), Merck (MRK).
- Rabies mRNA Vaccine: In development with GlaxoSmithKline.
Market Dynamics
Industry Overview
The mRNA therapeutics market is rapidly growing, driven by the success of mRNA vaccines and increasing interest in mRNA-based therapies for various diseases.
Positioning
CureVac is a pioneer in mRNA technology but faces strong competition from companies with more advanced mRNA platforms and products. Their mRNA tech needs improving to be competitive.
Total Addressable Market (TAM)
The TAM for mRNA therapeutics is projected to reach billions of dollars. CureVac's positioning is dependent on successful pipeline development and partnerships; market analysts estimate that the market has the potential to reach $10 billion by 2027. CureVac needs to improve the market confidence in order to reach a sizable portion of the TAM.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology platform
- Experienced management team
- Strategic partnerships with major pharmaceutical companies
- Diversified pipeline targeting multiple therapeutic areas
Weaknesses
- Failed late-stage clinical trial for COVID-19 vaccine
- Limited financial resources compared to competitors
- Smaller product portfolio
- Dependence on partnerships for development and commercialization
Opportunities
- Expanding mRNA applications beyond vaccines
- Advancing personalized cancer immunotherapies
- Leveraging partnerships for global market access
- Developing novel mRNA delivery technologies
Threats
- Intense competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial risks
- Intellectual property disputes
- Manufacturing challenges for mRNA therapeutics
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
Competitive Landscape
CureVac faces significant challenges against larger and more established competitors like Moderna and BioNTech. The company's success hinges on developing differentiated mRNA therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, with periods of significant investment followed by setbacks.
Future Projections: Future growth depends on successful pipeline development and partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include focusing on mRNA cancer immunotherapies and expanding partnerships.
Summary
CureVac NV is pioneering in mRNA technology but needs to regain market confidence. It has several strong partnerships but faces intense competition. Successful pipeline development and strategic execution is critical for future growth. With its recent challenges in vaccine development, CureVac needs to improve their tech or risk losing market share.
Similar Companies
- MRNA
- BNTX
- GSK
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports, industry publications.
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly. Data is based on best available information and may have inaccuracies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CureVac NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-14 | CEO, MD & Member of Management Board Dr. Alexander Zehnder M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 999 | Website https://www.curevac.com |
Full time employees 999 | Website https://www.curevac.com | ||
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.